Lancet Glob Health:癌症生存率显著上升!《柳叶刀》公布12年中国癌症大数据分析!

2018-04-19 Yui 转化医学网

中国国家癌症中心统计数据显示,我国每年新发癌症病例超350万,死亡病例超200万,肺癌、乳腺癌、胃癌等是最常见的癌症。癌症防治难度大、疾病负担重,已成为严重危害人类健康的重大公共卫生问题之一。大量数据显示,2003年至2005年间,中国的癌症5年生存率远远低于发达国家,且呈现较大的地理区域差异,因此,人群癌症生存率的检测对全面把握癌症护理的整体有效性至关重要。

中国国家癌症中心统计数据显示,我国每年新发癌症病例超350万,死亡病例超200万,肺癌乳腺癌胃癌等是最常见的癌症。癌症防治难度大、疾病负担重,已成为严重危害人类健康的重大公共卫生问题之一。大量数据显示,2003年至2005年间,中国的癌症5年生存率远远低于发达国家,且呈现较大的地理区域差异,因此,人群癌症生存率的检测对全面把握癌症护理的整体有效性至关重要。

人群癌症生存率是评估癌症服务质量的关键指标,对癌症的早期发现和适当管理至关重要。人口水平上癌症患者的生存率与癌症治疗的质量和相关资金、政策密切相关。为适应国家经济的快速发展下人民群众的健康需求,中国政府在医疗保健体系的建设方面拨出了大量人力物力财力,尤其是2003年以来,中国政府更是加大了对医疗保健的投资,有效提高了癌症患者的5年生存率。

近期,《柳叶刀》杂志发布了一项覆盖2亿多人的人口调查,分析了2003-2015年间中国癌症患者生存率,反映了12年间中国的癌症生存实况,为今后中国癌症政策的制定和改进提供数据支持。

研究人员分析了中国17个癌症登记处的人群癌症数据,覆盖了23 400万人口,根据性别、年龄和地理区域分析了2003年至2015年间所有癌症总体和26种不同癌症类型的5年相对生存率。

数据显示,2003年至2013年间,共有678 842例浸润性癌症患者被诊断出来,其中659 732例(97.2%)有资格纳入最终分析。

对比2003-05和2012-15两个区间,发现患者的年龄标准化5年相对生存率从30.9%增至40.5%。

在2012-15年间,除食管和宫颈癌患者外,城市地区(46.7%)癌症患者的年龄标准化5年生存率均高于农村地区(33.6%),但农村地区的患者生存率改善程度高于城市地区。

另一方面,相对生存率随年龄增加而下降,生存率的增长趋势与研究期间医疗支出的上升趋势一致。

癌症总生存率升高

城乡差距减少



2003-15年间总体癌症的5年生存率

在这些数据覆盖的人群中,2003年-2015年的癌症总体存活率显着增加,这可能反映了这些地区癌症治疗质量的进步。虽然癌症生存的地理差异仍然存在,但城乡之间的生存差距随着时间的推移而缩小。洞察这些趋势将有助于地域性癌症治疗政策的制定。

这项研究提供了中国最新的癌症生存率地理和时间差距的大数据,帮助研究人员了解这些地区癌症患者的生存状态,以及最近十年预后的变化状况。即使调整了性别和病例组合,总体癌症患者的5年生存率依旧呈明显上升状态,其中食道癌、胃癌、喉癌、骨癌、子宫颈癌、子宫癌、膀胱癌和甲状腺癌这八种癌症的5年生存率显着提高,总体癌症相对生存率随时间稳步提高,这表明中国这些地区人群的癌症护理质量总体上有所改善。

多种因素改善生存率

研究人员指出,癌症存活率的增加可归因于多种因素,包括初级保健服务的改善,诊断设施的改进以及治疗有效性的提高,还有可能与过度诊断有关。例如甲状腺癌的5年相对生存率的显着增加就可能反映了过度诊断,新成像技术的使用导致甲状腺小而缓慢生长的结节病例也被诊出。而食道癌、胃癌、宫颈癌和子宫癌的生存率提高的主要原因可能是有效治疗的增加。自2003年以来,人民保险覆盖范围扩大,使得及时有效的治疗成为可能。伴随着生存趋势的改善,胃癌和食道癌的死亡率也有所下降。

随着时间的推移,癌症存活率显着增加,即使数据显示城乡癌症患者仍然存在生存差距,但这种差距随着时间的推移逐渐缩小。政府按比例分配更多卫生保健资源到农村地区帮助改善癌症护理的举措有助于减少地区之间的生存差距,而社会经济状况,癌症政策和治疗效果都可以影响癌症的预后。目前中国实行的癌症政策有助于提高癌症患者,特别是农村和偏远地区的癌症患者的生存率。

癌症生存率存在年龄差异

65岁以上老年癌症缺陷



癌症患者生存率的年龄差异

癌症患者的生存率同样存在年龄差异,这也是一个重要的公共卫生问题,需要进一步关注。研究发现我国老年癌症群体(> 65岁)存在生存缺陷,这是因为老年患者的诊断多在疾病中后期,同意并发更多的合并症,因此不太可能得到根治性治疗,而且社会的对老年患者救治的积极性也影响老年癌症患者的生存率。另一方面,男性和女性癌症患者的生存率差异为10.0-13.9%,女性患者的存活率通常优于男性患者,目前仍需要相关的临床数据才能进一步解释这些差距。

总之,这些数据显示中国2003 - 15年间整体癌症存活率的显着改善,然而,癌症生存率仍然存在城乡差距,因此需要不断挺高癌症治疗质量同时提高所有人群的癌症治疗公平性。中国农村和城市地区持续存在的生存差距对未来的癌症控制具有重要意义,因此需要进一步研究确定城乡生存差距的根本原因,以便决策者能够适当地实施有针对性的干预措施以减少或消除差距。

原始出处:

Hongmei Zeng,et al.Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries.Lancet Glob Health.Volume 6, No. 5, e555–e567, May 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829592, encodeId=12a01829592e3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 11 06:12:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861212, encodeId=9e761861212b3, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Jan 02 23:12:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945813, encodeId=aee719458134d, content=<a href='/topic/show?id=21fde1416b9' target=_blank style='color:#2F92EE;'>#癌症生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71416, encryptionId=21fde1416b9, topicName=癌症生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 31 11:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308365, encodeId=055a308365b0, content=任何病都需要吃得起的药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Mon Apr 23 05:25:35 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307914, encodeId=b0a630e9146b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 21 12:03:06 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256649, encodeId=c5bf1256649d8, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621714, encodeId=6e681621e14bd, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307535, encodeId=5e9e30e535c2, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Apr 20 07:36:33 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307352, encodeId=7ac430e35234, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=673d1470045, createdName=szxy_001, createdTime=Thu Apr 19 19:48:47 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
    2018-08-11 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1829592, encodeId=12a01829592e3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 11 06:12:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861212, encodeId=9e761861212b3, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Jan 02 23:12:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945813, encodeId=aee719458134d, content=<a href='/topic/show?id=21fde1416b9' target=_blank style='color:#2F92EE;'>#癌症生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71416, encryptionId=21fde1416b9, topicName=癌症生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 31 11:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308365, encodeId=055a308365b0, content=任何病都需要吃得起的药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Mon Apr 23 05:25:35 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307914, encodeId=b0a630e9146b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 21 12:03:06 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256649, encodeId=c5bf1256649d8, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621714, encodeId=6e681621e14bd, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307535, encodeId=5e9e30e535c2, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Apr 20 07:36:33 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307352, encodeId=7ac430e35234, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=673d1470045, createdName=szxy_001, createdTime=Thu Apr 19 19:48:47 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
    2019-01-02 shizhenshan
  3. [GetPortalCommentsPageByObjectIdResponse(id=1829592, encodeId=12a01829592e3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 11 06:12:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861212, encodeId=9e761861212b3, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Jan 02 23:12:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945813, encodeId=aee719458134d, content=<a href='/topic/show?id=21fde1416b9' target=_blank style='color:#2F92EE;'>#癌症生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71416, encryptionId=21fde1416b9, topicName=癌症生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 31 11:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308365, encodeId=055a308365b0, content=任何病都需要吃得起的药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Mon Apr 23 05:25:35 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307914, encodeId=b0a630e9146b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 21 12:03:06 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256649, encodeId=c5bf1256649d8, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621714, encodeId=6e681621e14bd, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307535, encodeId=5e9e30e535c2, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Apr 20 07:36:33 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307352, encodeId=7ac430e35234, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=673d1470045, createdName=szxy_001, createdTime=Thu Apr 19 19:48:47 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1829592, encodeId=12a01829592e3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 11 06:12:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861212, encodeId=9e761861212b3, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Jan 02 23:12:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945813, encodeId=aee719458134d, content=<a href='/topic/show?id=21fde1416b9' target=_blank style='color:#2F92EE;'>#癌症生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71416, encryptionId=21fde1416b9, topicName=癌症生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 31 11:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308365, encodeId=055a308365b0, content=任何病都需要吃得起的药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Mon Apr 23 05:25:35 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307914, encodeId=b0a630e9146b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 21 12:03:06 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256649, encodeId=c5bf1256649d8, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621714, encodeId=6e681621e14bd, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307535, encodeId=5e9e30e535c2, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Apr 20 07:36:33 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307352, encodeId=7ac430e35234, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=673d1470045, createdName=szxy_001, createdTime=Thu Apr 19 19:48:47 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
    2018-04-23 121ff658m46暂无昵称

    任何病都需要吃得起的药!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1829592, encodeId=12a01829592e3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 11 06:12:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861212, encodeId=9e761861212b3, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Jan 02 23:12:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945813, encodeId=aee719458134d, content=<a href='/topic/show?id=21fde1416b9' target=_blank style='color:#2F92EE;'>#癌症生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71416, encryptionId=21fde1416b9, topicName=癌症生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 31 11:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308365, encodeId=055a308365b0, content=任何病都需要吃得起的药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Mon Apr 23 05:25:35 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307914, encodeId=b0a630e9146b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 21 12:03:06 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256649, encodeId=c5bf1256649d8, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621714, encodeId=6e681621e14bd, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307535, encodeId=5e9e30e535c2, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Apr 20 07:36:33 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307352, encodeId=7ac430e35234, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=673d1470045, createdName=szxy_001, createdTime=Thu Apr 19 19:48:47 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
    2018-04-21 121832a9m88暂无昵称

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1829592, encodeId=12a01829592e3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 11 06:12:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861212, encodeId=9e761861212b3, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Jan 02 23:12:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945813, encodeId=aee719458134d, content=<a href='/topic/show?id=21fde1416b9' target=_blank style='color:#2F92EE;'>#癌症生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71416, encryptionId=21fde1416b9, topicName=癌症生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 31 11:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308365, encodeId=055a308365b0, content=任何病都需要吃得起的药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Mon Apr 23 05:25:35 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307914, encodeId=b0a630e9146b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 21 12:03:06 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256649, encodeId=c5bf1256649d8, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621714, encodeId=6e681621e14bd, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307535, encodeId=5e9e30e535c2, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Apr 20 07:36:33 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307352, encodeId=7ac430e35234, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=673d1470045, createdName=szxy_001, createdTime=Thu Apr 19 19:48:47 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1829592, encodeId=12a01829592e3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 11 06:12:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861212, encodeId=9e761861212b3, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Jan 02 23:12:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945813, encodeId=aee719458134d, content=<a href='/topic/show?id=21fde1416b9' target=_blank style='color:#2F92EE;'>#癌症生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71416, encryptionId=21fde1416b9, topicName=癌症生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 31 11:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308365, encodeId=055a308365b0, content=任何病都需要吃得起的药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Mon Apr 23 05:25:35 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307914, encodeId=b0a630e9146b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 21 12:03:06 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256649, encodeId=c5bf1256649d8, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621714, encodeId=6e681621e14bd, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307535, encodeId=5e9e30e535c2, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Apr 20 07:36:33 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307352, encodeId=7ac430e35234, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=673d1470045, createdName=szxy_001, createdTime=Thu Apr 19 19:48:47 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1829592, encodeId=12a01829592e3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 11 06:12:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861212, encodeId=9e761861212b3, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Jan 02 23:12:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945813, encodeId=aee719458134d, content=<a href='/topic/show?id=21fde1416b9' target=_blank style='color:#2F92EE;'>#癌症生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71416, encryptionId=21fde1416b9, topicName=癌症生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 31 11:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308365, encodeId=055a308365b0, content=任何病都需要吃得起的药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Mon Apr 23 05:25:35 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307914, encodeId=b0a630e9146b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 21 12:03:06 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256649, encodeId=c5bf1256649d8, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621714, encodeId=6e681621e14bd, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307535, encodeId=5e9e30e535c2, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Apr 20 07:36:33 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307352, encodeId=7ac430e35234, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=673d1470045, createdName=szxy_001, createdTime=Thu Apr 19 19:48:47 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
    2018-04-20 kafei

    了解一下谢谢

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1829592, encodeId=12a01829592e3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 11 06:12:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861212, encodeId=9e761861212b3, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Jan 02 23:12:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945813, encodeId=aee719458134d, content=<a href='/topic/show?id=21fde1416b9' target=_blank style='color:#2F92EE;'>#癌症生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71416, encryptionId=21fde1416b9, topicName=癌症生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Oct 31 11:12:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308365, encodeId=055a308365b0, content=任何病都需要吃得起的药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41962298363, createdName=121ff658m46暂无昵称, createdTime=Mon Apr 23 05:25:35 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307914, encodeId=b0a630e9146b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 21 12:03:06 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256649, encodeId=c5bf1256649d8, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621714, encodeId=6e681621e14bd, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Sat Apr 21 09:12:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307535, encodeId=5e9e30e535c2, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Apr 20 07:36:33 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307352, encodeId=7ac430e35234, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=673d1470045, createdName=szxy_001, createdTime=Thu Apr 19 19:48:47 CST 2018, time=2018-04-19, status=1, ipAttribution=)]
    2018-04-19 szxy_001

    学习了

    0

相关资讯

Cell Rep:基因图谱为癌症精准化疗奠定基础

尽管靶向癌症药物取得了巨大的成功,并且有望实现新型免疫疗法,但绝大多数被诊断有癌症的患者仍首先接受化疗。现在,UCSF研究人员使用计算生物学技术开展的一项新研究,可以使医生更倾向于使用患者肿瘤的基因谱来选择最少副作用和最佳成功机会的化疗方案。

上海女性常见癌症是什么?甲状腺癌

问:上海女性最常见癌症是什么?答:甲状腺癌。上海疾控发布上海最新肿瘤登记报告数据,2014年共诊断新发癌症病例6.8万例。全市癌症发病率为477.8/10万,约为欧美发达国家的2/3。报告显示,2014年,本市男性癌症发病率略高于女性。男性中,肺癌、大肠癌、胃癌、肝癌和前列腺癌是最常见癌症。男性发病第一位的肺癌占所有男性新发癌症的22.3%。上海女性最常见的癌症依次是甲状腺癌、乳腺癌、肺癌、大肠癌

人工智能已在我国大规模应用于癌症早期筛查

全世界首台人工智能宫颈癌诊断机器人“兰丁”,能以极高的工作效率,从数字化图像里找到癌细胞的踪迹,实现完全自动化的诊断。目前,诊断机器人已在国内数百家医疗机构投入应用,并在山西、湖北、河南、云南等地,开始被大规模应用于边远地区农村妇女宫颈癌筛查的政府项目。

Ann Rheum Dis:有癌症史的RA患者,bDMARD治疗增加SMN风险?

2018年4月,发表在《Ann Rheum Dis》的一项丹麦基于人群的队列研究,考察了生物类改善病情类抗风湿药(bDMARD)治疗的类风湿关节炎(RA)患者第二恶性肿瘤(SMN)和死亡风险。

日立将开展通过尿检判断是否患癌的实验

据日本《朝日新闻》4月16日报道,日立制作所和日本名古屋大学医学部附属医院自本月起将开始进行实证试验,通过尿液检查判断是否罹患癌症。这在全球尚属首次。

肿瘤医生:未来十年不想得癌症!不得不知的8个癌症真相!

癌症已经成为威胁人类健康的第一大杀手,癌症的早期检查预防治疗对预后影响非常大。然而在癌症的认识和治疗过程中很多人对癌症只有恐惧,对癌症的认识还停留在"患癌就死人"的阶段,其实癌症并不可怕,就让我们一起来了解癌症的真相吧。